Health Care·Biotechnology·$2.6B
ADMA Biologics Inc is a biotechnology company focused on developing and commercializing specialty plasma-derived biologics. With a market cap of $3 billion, it plays a crucial role in the healthcare sector, particularly in providing treatments for immunodeficient patients.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health.
Revenue Growth
Revenue growth will indicate the company's ability to expand its market presence and drive sales.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
+38.38%
Avg Stock Reaction
+1.29%
In Q4 2025, ADMA reported an EPS of $0.20, which was a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
Management Promises & Guidance
Overall, expectations are mixed as there are no analyst estimates available, creating uncertainty around the upcoming earnings report.
Bull Case
If ADMA can report strong EPS and show positive revenue growth, it could signal robust demand for its products and lead to a significant stock price increase.
Bear Case
Conversely, if the company fails to meet prior EPS levels or provides weak guidance, it could lead to a decline in investor confidence and a drop in stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health.
Revenue Growth
N/ARevenue growth will indicate the company's ability to expand its market presence and drive sales.
Product Pipeline Updates
N/AUpdates on the product pipeline can signal future revenue potential and market competitiveness.
The print will turn on these two things.
Q1
What will the EPS be for Q1-2026?
EPS is a critical measure of profitability, and any deviation from expectations could significantly impact stock performance.
Q2
What updates can be provided regarding the product pipeline?
Insights into the product pipeline will help investors gauge future revenue potential and the company's competitive position.
Why consensus could be wrong
The market may be underestimating the potential for ADMA to exceed prior EPS levels due to recent improvements in operational efficiency.
Supporting Evidence
ADMA has historically beaten EPS estimates 71% of the time, indicating a strong track record.
Recent product developments could lead to higher-than-expected demand, which the market may not fully appreciate.
Key Risk
If the company reports an EPS significantly above $0.20, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is closely watching ADMA's ability to maintain or improve profitability, especially after a mixed earnings history.
Bull Confirmed If
An EPS of $0.25 or higher would confirm strong operational performance and investor confidence.
Bear Confirmed If
An EPS below $0.15 would suggest ongoing challenges and could lead to negative sentiment.
Implied Move
±N/A
Historical Avg
±2.7%
There is no available options market data to gauge investor sentiment leading into the earnings report.
Options are pricing ±22.0% while ADMA has averaged ±2.7% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter beat setup
n=30Fade rate: 17 of 29 (59%)
This setup has shown that 59% of similar instances faded within 5 days, suggesting that any initial positive reaction may not hold in the long term.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If ADMA beats expectations, history suggests the stock could rise around +0.42%, confirming a positive outlook for the company.
In-Line / Cautious
If results are in line but management provides cautious commentary, the stock may see little movement as investors reassess their expectations.
Miss
A miss could lead to a decline around +3.59%, reflecting disappointment in the company's performance and future outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026